Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNM-Au8 in Multiple Sclerosis
NCT03993171Phase 2Completed
- Sponsor
- Clene Inc.
- Start
- Dec 2019
- Primary completion
- May 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CNM-Au8 in multiple sclerosis (MS), sponsored by Clene Inc.. Started Dec 2019; status: completed.
02
Drugs
CNM-Au8
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03993171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993171.